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32 The Journal of Thoracic and Cardiobjectives: Despite the potential limitation of organ availability, several surgical
roups have advocated preferential bilateral lung transplantation because of its
emonstrated long-term survival advantage. Comparative results for single and
equential double lung transplantation performed at a single center are evaluated to
etermine whether such a policy improves patient outcome.
ethods: A retrospective analysis of demographic and outcome data for patients
ndergoing lung transplantation was performed. Patients were grouped as single or
ouble lung recipients and segregated into diagnostic categories according to the
ung allocation scoring system. Era terciles were chosen on the basis of year of
ransplant, operating surgeon, and transplant volume.
esults: Between November 1990 and September 2005, 344 lung transplant proce-
ures were performed in 339 patients. Over three time periods evaluated, the
roportion of patients undergoing double lung transplant procedures increased.
verall survivals at 3 months and 1, 3, and 5 years were 89%, 79%, 60%, and 52%,
espectively. After adjusting for lung recipient characteristics, survival after double
ung transplantation was improved when compared with single lung transplantation
P  .020). Overall patient survival among the three time periods was not signif-
cantly different at 30 days and 1 and 3 years despite increasing maximal donor
rgan ischemia times.
onclusions: In this single-center study, despite longer median allograft ischemic
imes, as well as greater patient acuity as determined by listing diagnosis, overall
arly and midterm patient survival has remained higher than nationally reported
gures. Bilateral lung transplantation in eligible patients is the procedure of choice.
ulmonary transplantation has been established as an effective treatment
option for selected patients with end-stage lung disease. Broad application of
this therapy is hampered primarily by the limited availability of suitable
onor organs. Application of “extended” donor criteria,1,2 government-led initia-
ives to increase public awareness of the need for organ donation, and, more
ecently, development of protocols for living-related lobar transplantation or for
ung donation after cardiac death all may increase the number of available organs for
ransplantation.3 Evaluation of international registry data has demonstrated con-
ently that survival is greater after bilateral lung transplantation than single lung
ransplantation, although this difference appears to depend on a variety of factors,
ncluding the age of the recipient and etiology of end-stage lung disease.4
The purpose of this retrospective study is to evaluate our single-center experience
f pulmonary transplantation and particularly the impact of bilateral organ trans-
lantation. We report both overall and disease-dependent survival as well as reasons
or hospital mortality.
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TXaterials and Methods
atients
ll adult lung transplants performed at the University of Michigan,
nn Arbor, between November 1990 and September 2005 were
ncluded in this review. Nine patients who received heart-lung
ransplantation at our institution were excluded. Retrospective
nalyses of both transplant records and a computerized database
ere performed. Approval for this study, including waiver of
nformed consent, was obtained from the University of Michigan
nstitutional Review Boards. Recipient diagnoses were reviewed
nd classified into four groups: group A, obstructive lung diseases;
roup B, pulmonary hypertensive disorders; group C, bronchiec-
atic diseases including cystic fibrosis; and group D, pulmonary
brotic diseases, as designated by the lung allocation scoring
ystem.5 Recipient selection was in accordance with guideli
stablished by the International Society of Heart and Lung Trans-
lantation (ISHLT) and the American Thoracic Society.6 In our
nitial analysis, patients were segregated by year of transplantation
nd operating surgeon into terciles ranging from 1990-1995, 1996-
000, and 2001-2005.
onor Factors
e adhered to general selection criteria for selection of suitable
adaveric donor organs.1,2 No patients received either livin
elated lung transplant or organs obtained from non–heart beating
onors. Pulmoplegia consisted of Euro-Collins solution until 1998
nd University of Wisconsin solution thereafter.
ecipient Procedure
efore anesthetic induction, the majority of our patients had epidural
atheters placed. Operative technique varied with the operating sur-
eon. Generally, single lung transplantation was performed via pos-
erolateral thoracotomy. Bilateral lung transplantation was performed
ia bilateral sequential posterolateral thoracotomy or via bilateral
nterolateral thoracotomy with or without transverse sternotomy.
elective use of inhaled nitric oxide intraoperatively and postop-
ratively and intraoperative cardiopulmonary bypass was used for
atients with pulmonary hypertension or hypoxemia. For bilateral
ung transplantation, total ischemic time indicated time to reper-
usion of the second lung. During this study period, perioperative
ytolytic antibody therapy was not administered.
nfection Prophylaxis
erioperative antibacterial agents consisted of vancomycin and
eftazidime for the first 48 hours after transplant and was adjusted
ccording to intraoperative bronchial cultures. Patients at risk for
Abbreviations and Acronyms
CI  confidence interval
HR  hazard ratio
ISHLT International Society of Heart and Lung
Transplantation
SRTR  Scientific Registry of Transplant Recipientsytomegalovirus infection were treated with postoperative ganci- .
The Journal of Thoraciclovir for 21 days. Pneumocystis carinii prophylaxis was achieved
ith trimethoprim/sulfamethoxazole or dapsone.
mmunosuppression
atients received preoperative oral cyclosporine (5 mg/kg). Post-
peratively, intravenous cyclosporine was administered, beginning
t 3 mg/h, and the infusion rate was adjusted to maintain serum
yclosporine levels at 200 to 250 ng/mL. Patients were transitioned
o lipid-emulsified cyclosporine (Neoral; Novartis Pharmaceuticals
orporation, East Hannover, NJ). Azathioprine therapy was initi-
ted in the immediate postoperative period, 2 mg/kg intravenously/
rally daily, adjusting doses for leukopenia (white blood cell count
3500/mm3). Patients received 1000 mg methylprednisolone in-
ravenously intraoperatively at organ reperfusion and then tapered
0% per day from 100 mg intravenously/orally twice daily to 20
g/day.
tatistical Analysis
ospital mortality was defined as in-hospital death at initial hos-
italization for transplantation. Continuous data were compared
etween groups by the 2-sample t test. Categorical data were
nalyzed by 2 tests or, alternatively, by the Fisher exact tests for
omparisons with small expected cell counts. Multivariate survival
nalysis was performed with the Cox regression method.7
esults
atient Characteristics
etween 1995 and 2005, 459 patients were listed for
ransplantation at the University of Michigan (Figure
ithin each year of listing, on average, 57.6%  6.4% of
atients listed went on to transplantation whereas 26.1% 
0.0% of patients died. The median waiting list time for
atients undergoing transplantation since 1995 was 7.3
onths (range 3.5–27.2 months).
Between November 1990 and September 2005, a total of
39 patients underwent 344 transplant operations, including
patients undergoing retransplantation, with annual distri-
ution and median waiting list time illustrated in Figu
he distribution of specific disease processes is detailed in
able 1. Of 249 patients in group A, 37 were diagnosed
1-antitrypsin deficiency. The sex distributions of the single
nd double lung transplant patient populations were similar,
ut the single transplant recipients tended to be older (53.8
ears vs 44.7 years; P  .001).
Proportionately more patients in diagnosis group A re-
eived single versus double lung transplants compared with
he other diagnosis groups. The relative proportion of dou-
le lung transplants varied significantly across 5-year time
eriods, with the 1996-2000 era dominated by single lung
ransplants, and a substantial increase in double lung trans-
lants more recently from 2001 to 2005. The average isch-
mic time for double transplants was significantly greater
han that for single transplants (418 vs 233 minutes; P 
001). Accordingly, median graft ischemia times increased
and Cardiovascular Surgery ● Volume 133, Number 2 533
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TXver our three eras of transplantation from 218 minutes to
31 and 285 minutes (P  .001).
urvival and Hospital Mortality
ospital mortality occurred in 34 patients (10%) and was
reatest (33%) for patients with pulmonary hypertensive
isorders (group B), including 1 patient with Eisenmenger
yndrome and 4 with primary pulmonary hypertension
Table 2). In contrast, there were no in-hospital deaths 
atients with cystic fibrosis or immune deficiency (group C).
rimary graft dysfunction (n  12), infection (n  8), and
ntraoperative complications (n  4) were the chief reasons
or in-hospital mortality. Two deaths each were due to
ronchial anastomotic disruption, late respiratory failure,
nd complications resulting from gastrointestinal perfora-
ion. Deaths were attributed to acute rejection, myocardial
ABLE 1. Baseline characteristics, lung transplant patient
Single (n 
Gender (M/F) 129/136
Mean age at aransplant (y) 53.8 (SD 8
Mean ischemia time (min) 233 (SD 7
Diagnosis group A (n  249) 206 (82.7%)
Diagnosis group B (n  15) 10 (66.7%)
Diagnosis group C (n  16) 0 (0.0%)
Diagnosis group D (n  59) 49 (83.1%)
Transplant years 1990-1995 63 (76.8%)
Transplant years 1996-2000 117 (90.7%)
Transplant years 2001-2005 85 (66.4%)
P values correspond to the Fisher exact test for categorical variables a
ompare the proportion of single/double transplants in each category with all o
34 The Journal of Thoracic and Cardiovascular Surgery ● Febrschemia, stroke, and tension pneumothorax in 1 patient
ach.
etransplantation
ive patients underwent single lung retransplantation
Table 3). In our early experience, 3 patients receiv
psilateral retransplant for primary graft dysfunction, with 2
atients dying in the hospital or in the operating room.
aving been listed urgently, each of these patients was on
he waiting list for less than 1 week. An additional 2 patients
ubsequently underwent elective retransplantation for bron-
hiolitis obliterans syndrome and are ongoing survivors.
ultivariate Analysis
he overall 3-month and 1-, 3-, and 5-year survivals (95%
onfidence intervals [CI]) for the average study participant
Figure 1. Number and type of lung
transplant performed and median wait-
ing list times (months) annually.
 339)
Double (n  74) P value*
35/39 P  .937
44.7 (SD 9.42) P  .001
418 (SD 70) P  .001
43 (17.3%) P  .002
5 (33.3%) P  .334
16 (100.0%) P  .001
10 (16.9%) P  .387
19 (23.2%) P  .760
12 (9.3%) P  .001
43 (33.6%) P  .001
est for continuous variables. P values for diagnosis and year categoriess (n
265)
.16)
4)
nd t t
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TXere 0.89 (0.86, 0.93), 0.79 (0.75, 0.84), 0.60 (0.55, 0.66),
nd 0.52 (0.46, 0.59) (Figure 2, A). Results from the mu
ivariate Cox model (Table 4, Figure 2, B) indicated tha
fter adjusting for diagnosis, sex, time of transplant, and age
t transplant, double lung transplant patients had signifi-
antly improved survival over single transplant patients,
ith a hazard ratio (HR) of 0.583 (95% CI, 0.371, 0.917;
 .020). This survival advantage was not altered by
ncluding or excluding the 16 patients in group C undergo-
ng bilateral transplantation. We observed marginally sig-
ificant improved survival for group A with bilateral lung
ransplantation when compared with single lung transplan-
ation (HR 0.617, 95% CI 0.368,1.034; P  .067).
Of the 4 diagnosis groups (Figure 2, C), after adjusting
or transplant type, sex, time of transplant, and age, patients
n diagnosis group B experienced the worst survival, with an
R of 3.365 as compared with patients in diagnosis group
(95% CI 1.685, 6.720; P  .001).
Sex, year of transplant, and age at transplant were not
tatistically significant in our analysis. Interactions between
ype of transplant and these other variables were also ex-
lored, but no statistically significant interactions were dis-
overed, although power for assessing interactions was lim-
ted. In the subset of 288 patients with known ischemic
ABLE 2. Hospital mortality
Overall 34/339 (10.0%)
Era
1990-1995 9/82 (11.0%)
1996-2000 16/129 (12.4%)
2001-2005 9/128 (7.0%)
Diagnosis group
A 23/249 (9.2%)
B 5/15 (33.3%)
C 0/16
D 6/59 (10.2%)
ABLE 3. Baseline characteristics and survival times for t
atient Sex TX type Diagnosis Waiting time (d)
1 M Single (L) PF 7
Single (L) 1
2 F Single (R) COPD 2
Single (R) 6
3 M Single (L) PF 205
Single (L) 1
4 M Single (L) PF 357
Single (R) 1200
5 M Single (R) PF 363
Single (R) 93X, Transplant; L, left; R, right; PF, pulmonary fibrosis; COPD, chronic obstructive
The Journal of Thoracicimes, no relationship to posttransplant survival was ob-
erved (HR 1.005, 95% CI 0.874, 1.160; P  .94).
iscussion
he use of pulmonary transplantation for patients with
nd-stage lung disease has changed dramatically as a result
f advances in donor management, organ procurement, op-
rative approach, and perioperative treatment. Our trans-
lantation program, initiated in 1990, has benefited from the
urgical outcomes and analyses reported by several la
enters.8-11 Our outcomes likely reflect patient selectio
ith the large majority of our patients undergoing trans-
lantation for obstructive lung diseases (249/339, 73.4%).
atients with restrictive lung diseases (59/339, 17.4%) con-
tituted the next largest group.
As reported in several single-center studies and in the
SHLT registry, we observed that patients with pulmonary
ypertensive disorders at our institution had significantly
orse outcomes than our entire cohort. Although in our
urrent practice such patients will undergo bilateral lung
ransplantation, early in our experience we elected to per-
orm single lung transplantation for this group, since early
ata did not indicate any survival advantage favoring bilat-
ral transplantation.12 We did not discern any difference
ospital mortality between single and bilateral lung trans-
lant recipients for the 15 patients in group B, nor did we
bserve any significant differences in overall survival at-
ributable to listing diagnosis, likely reflecting the smaller
ohorts of patients for diagnostic groups other than patients
ith obstructive lung disease.
Patients undergoing bilateral sequential pulmonary trans-
lantation had significantly improved overall survival com-
ared with those receiving single lung transplantation, even
hen adjusting for age at transplantation and listing diag-
osis group. Notably, we observed no hospital mortality
mong patients with cystic fibrosis or immune deficiency–
elated lung diseases (group C), for which only bilateral
ung transplantation was offered. Current data suggest that
patients requiring retransplant
Graft survival (d) Ischemia (h) Year of TX Age at TX (y)
37* N/A 1991 37
5310* N/A 1991 37
193* N/A 1991 57
29 N/A 1991 57
8* 4:41 1994 46
0 N/A 1994 46
2002* 4:25 1996 30
1204* 3:57 2002 35
640* 6:25 2002 57
564* 4:42 2004 59he 5pulmonary disease. *Patient was still alive at the end of this time period.
and Cardiovascular Surgery ● Volume 133, Number 2 535
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TXFigure 2. A, Overall survival for 339 patients undergoing lung transplantation at the University of Michigan between
November 1990 and September 2005. Cox multivariate survival, with 95% confidence limits (dotted lines), adjusted
for transplant type, recipient sex, age, year of transplantation, and listing diagnosis. B, Cox multivariate survival
by bilateral (DLT) or single lung transplantation (SLT), adjusted for recipient sex, age, year, and diagnosis at
transplantation. C, Cox multivariate survival by listing diagnosis, adjusted for transplant type, recipient sex, age,
and year at transplantation.
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TXurkholderia cepacia genomovar subtypes are important in
etermining transplant outcomes.13 In the past, colonizatio
ith B cepacia had been associated with poorer outcomes
fter transplantation14 and was therefore considered a co-
raindication to listing in our population during the period of
he study.
There is considerable debate regarding the utility of
ulmonary transplantation in the treatment of chronic ob-
tructive pulmonary disease. Our data are consistent with
egistry data and single-center experiences15,16 that have
emonstrated significantly improved survival for patients
ith obstructive lung diseases undergoing bilateral rather
han single lung transplantation. In an analysis using regis-
ry data, Hosenpud and associates17 demonstrated that al-
hough patients undergoing transplantation for interstitial
ulmonary fibrosis and cystic fibrosis obtained a benefit in
verall survival when compared with waiting list survival,
he predicted waiting list survival for patients with chronic
bstructive pulmonary disease, up to the 2-year period of
ollow-up in the study, exceeded posttransplantation sur-
ival. These authors cautioned, however, that non–survival
elated benefits, particularly posttransplantation quality of
ife, could not be accounted for in their analysis. We did not
etermine whether spirometry or exercise tolerance im-
roved significantly in bilateral lung recipients, as has been
emonstrated by others.18
With the implementation in May 2005 of the lung 
ation score system,19 donor organ allocation in the Unit
tates is currently assigned on the basis of estimated pre-
ransplant mortality and postoperative survival, with the
oal of developing a regional need-based system, rather
han relying on waiting list time accrual. With more urgent
atients undergoing transplantation, we may see a slight
ncrease in posttransplant morbidity and mortality in our
atient population, but also a reduction in deaths on the lung
aiting list. The Scientific Registry of Transplant Recipi-
nts (SRTR) has developed a thoracic simulated allocation
odel that potentially can provide further insight, using
ationally collected data, regarding the impact on waiting
ABLE 4. Multivariate Cox survival model for 339 lung tra
Variable HR
Type of transplant (double vs single) 0.5
Diagnosis group A 1.0
Diagnosis group B (compared with A) 3.3
Diagnosis group C (compared with A) 0.8
Diagnosis group D (compared with A) 1.0
Sex (M vs F) 0.9
Time of transplant (y since 1990) 1.0
Age at transplant (y) 1.0
R, Hazard ratio; CI, confidence interval; REF, reference.ist mortality of performing bilateral lung transplantation t
The Journal of Thoracic-
ore frequently. It remains to be seen whether our patients
ith obstructive lung disease will receive organ offers at a
ate similar to our past experience since these patients will
ave less urgency than patients with other lung diagnoses
hen ordered according to the lung allocation score.
Of interest, we observed that in our limited experience
ith retransplantation, as has been reported elsewhere, pa-
ients with acute graft dysfunction fared poorly.20,21 How-
ver, the 2 patients with pulmonary fibrosis undergoing
etransplantation for chronic rejection have been able to
chieve survival approaching that of their initial organ
ransplantation. Given that several studies have argued that
verall survival does not appear to differ22 and may actually
e worse23 with bilateral rather than single lung transpl-
ation, particularly for patients with restrictive lung dis-
ases, it remains unknown whether sequential unilateral
ransplantation rather than bilateral lung transplantation
hould be offered, especially in the context of the current
ung allocation score.
onclusions
s we and others have demonstrated, acceptable patient
urvival after pulmonary transplantation is consistent and
eproducible across institutions and diagnoses. Since the
rst lung transplant in June 1963 by Dr James Hardy,24 with
ontinued re-evaluation using both registry data and indi-
idual institutional experiences over the past several de-
ades, both operative technique and perioperative manage-
ent after lung transplantation have evolved and improved.
ow with measures being initiated to provide more equita-
le organ allocation, it becomes imperative to identify fac-
ors that predict not only survival but benefits in quality of
ife. This retrospective study has provided benchmark sur-
ival data that will allow our institution and ideally others to
ngage in ongoing quality assessment and improvement to
ontinue optimizing surgical and long-term outcomes after
ulmonary transplantation.
Dr Chang was the primary author and principal investigator of
nt recipients
95% CI for HR P value (HR  1)
(0.371, 0.917) P  .020
REF REF
(1.685, 6.720) P  .001
(0.231, 2.964) P  .772
(0.669, 1.571) P  .908
(0.710, 1.303) P  .803
(0.972, 1.063) P  .473
(0.988, 1.031) P  .380nspla
83
00
65
28
26
62
17
09he study; he was responsible for the design of the study, analysis,
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iscussion
r Shaf Keshavjee (Toronto, Ontario, Canada). I congrat-
late the authors on an excellent collection of their data
emonstrating continuously improved outcomes after lung
ransplantation in their institution.
As you know, we in Toronto also favor bilateral lung
ransplantation strongly, with 80% to 90% of our transplants
n our entire program being bilateral lung transplants. In
ssessing the results of bilateral lung transplantation from
oronto, St Louis, and Duke University, we found a signif-
cant functional and survival benefit for bilateral lung trans-
lantation over single lung transplantation in patients with
mphysema, but in the other disease categories the differ-
nce was less obvious.
In looking at your data, I have trouble reconciling your
onclusion with your own experience. You report that 75%
f your patients underwent transplantation for emphysema,
et when you analyzed that group you did not show a
ignificant advantage of bilateral over single lung transplan-
ation. I think your single lung transplant group was signif-
cantly disadvantaged in that the single lung transplant
atients in your institution were a full decade older. Having
ery high-risk recipients, that is, a single lung transplant for
ulmonary hypertension, also disadvantaged the single lung
ransplant group. So, your bilateral group had the advantage
f those 16 patients with cystic fibrosis who received a
ilateral lung transplant and your single lung transplant
roup had the disadvantage of 15 patients with pulmonary
uary 2007
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TXypertension and a 33% mortality. Did you analyze the
ilateral versus single transplant results by excluding that
ery high-risk group of single lung transplants for pulmo-
ary hypertension?
Dr Chang. Dr Keshavjee, thank you for your comments
nd insight. First, as an aside, I would like to point out that
t has been about 20 years to the day since the Toronto
roup published the results of their initial experience in the
ew England Journal of Medicine. That was with single
ransplantation for idiopathic pulmonary fibrosis. It is from
he successes and scientific inquiry of the Toronto, Barnes,
uke, and other major transplant centers that we hope to
uild our own program.
We did not exclude the patients undergoing single
ung transplant for pulmonary hypertensive disorders for
his presentation. I suspect that if we excluded that high-
isk group, as well as the 16 patients who underwent
ilateral transplantation for cystic fibrosis or immune-
elated bronchiectasis, we might see equalization of the
urvival curves. We looked at the patients undergoing
ingle or bilateral transplantation in group A, the patients
ith obstructive lung disease, and we did not observe a
ignificant difference in overall survival, with a P value of
07. That could be due to our distribution, which is weighted
eavily toward single lung transplantation so that we did not
ave enough numbers in our bilateral group to determine
ny statistical significance.
Dr Keshavjee. I am also interested in your comment
bout bilateral thoracotomies, posterolateral thoracotomies,
nd 4 intraoperative deaths. How many patients had bilat-
ral thoracotomies, and were those intraoperative deaths
elated to that?
Dr Chang. No, to my recollection we did not have an
perative death resulting from the patients being flipped
rom one side to the other.
Dr Keshavjee. My last question concerns your use of
ntravenous cyclosporine. Do you still do that? Most people
ave switched to using oral cyclosporine for a number of
dvantages related to achieving therapeutic levels and bio-
ogic activity.
Dr Chang. We used intravenous cyclosporine in the
mmediate postoperative period and transitioned to oral
ormulation, more recently Neoral, when patients were tol-
rating oral intake. More recently, we have stopped using
yclosporine completely, instead using tacrolimus either
ublingually or orally. Among the many reasons for which
e performed this study, with the initiation of the lung
llocation scoring system, we wanted to review our own
rior experience for future comparison. Having done this
nd with the addition of a new partner to our surgical group,
e found that we were holding calcineurin inhibitor therapy
intravenous cyclosporine) when patients had increased risk
or postoperative renal dysfunction. Since undertaking this g
The Journal of Thoracictudy we have switched over to tacrolimus, mycophenolate
ofetil, as well as steroids for our posttransplant immuno-
uppression regimen.
Dr Frederick L. Grover (Denver, Colo). This is
lways an interesting topic, and I know Shaf and Alec
nd I go round and round about this. At Colorado we
ave taken the attitude of single lung transplantation for
diopathic pulmonary fibrosis and for chronic obstructive
ulmonary disease in the older age groups, which gener-
lly we define as late 50s and 60s or 70s, partly depend-
ng on how frail the patients are as well. We have had
elatively good results with that plan. The way I always
ry to balance this is the shortage of organ donors and the
isk of death on the waiting list versus perhaps some
urvival advantage and quality of life advantage on pa-
ients with double lung versus single lung transplantation.
ndeed, when we were developing the scoring system for
ung allocation, we tried to weigh the risk of death on the
aiting list against the risk of an adverse outcome after
he lung transplant itself.
Have you taken into account, if you were to do double
ransplants, potentially how many patients on the waiting
ist might not get to transplantation and what would their
isk of dying be? I think you have to look at this more in
he whole public health type of big picture.
Dr. Chang. Thank you for your comments, Dr Grover, and
articularly for your contributions as part of the SRTR group
hat developed the lung allocation scoring system.
As far as how implementation of the lung allocation
coring system will affect our decisions to use bilateral
ransplantation, it is hard for me to predict what will happen
o our waiting list mortality. Our waiting list mortality
enerally runs about 10% to 20%, comparable to the waiting
ist mortality reported by Dr De Perrot. I do not know what
s going to happen as far as trying to increase the number of
ilateral transplants in our group further. That is a major
eason why we undertook this study, to see whether we
ould identify factors driving our decision to proceed with
ither single or bilateral transplant and to establish an in-
ernal benchmark, if you will, for our future efforts.
Dr Joshua R. Sonett (New York, NY). Let me ask one
uestion. In lieu of your data, with the new lung alloca-
ion scoring system, it appears, at least from our early
xperience, that it is harder for us to get lungs for even
elatively sick patients with pulmonary hypertension.
hat was your policy, or how do you think your group
ould work right now? Would you still use a single
ransplant or would you go with doubles for the pulmo-
ary hypertensive groups, even with the difficulty of
etting organs for them?
Dr Chang. Our preference has been recently for bi-
ateral transplants in the pulmonary arterial hypertension
roup, and we have observed the same thing, that their
and Cardiovascular Surgery ● Volume 133, Number 2 539
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TXcores are much lower than what we would like to see
iven how sick they are. That is one of the reasons we
ope that working with the SRTR we can potentially
ffect what their scoring system is set at. I do not have a
ood answer for that, but I think that it is important to try
o better identify the sicker patients with pulmonary
rterial hypertension. I have talked with our pulmonolo-40 The Journal of Thoracic and Cardiovascular Surgery ● Febrhen they are at death’s door, and the potential of what
e have is perhaps 32% mortality. I am not sure.
Dr Sonett. I think part of the problem is that nobody
s able to predict ahead of time when those patients are
oing to fall off the tightrope that they have been walking
n with the ever increasing array of medications to ame-
iorate the pulmonary hypertension.ists about this, and they send the patients to us basically Dr Chang. Right.uary 2007
